{"id":842434,"date":"2025-04-28T06:48:50","date_gmt":"2025-04-28T10:48:50","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/arvinas-shares-new-preclinical-combination-data-for-the-protac-bcl6-degrader-arv-393-at-the-2025-american-association-for-cancer-research-annual-meeting\/"},"modified":"2025-04-28T06:48:50","modified_gmt":"2025-04-28T10:48:50","slug":"arvinas-shares-new-preclinical-combination-data-for-the-protac-bcl6-degrader-arv-393-at-the-2025-american-association-for-cancer-research-annual-meeting","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/arvinas-shares-new-preclinical-combination-data-for-the-protac-bcl6-degrader-arv-393-at-the-2025-american-association-for-cancer-research-annual-meeting\/","title":{"rendered":"Arvinas Shares New Preclinical Combination Data for the PROTAC BCL6 Degrader, ARV-393, at the 2025 American Association for Cancer Research Annual Meeting"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"center\">\n        <em>\u2013 ARV-393 demonstrated strong synergistic antitumor activity, including complete regressions, in combination with standard-of-care chemotherapy, biologics, and select investigational oral small molecule inhibitors \u2013<\/em>\n      <\/p>\n<p align=\"center\">\n        <em>\u2013 Findings support continued evaluation of ARV-393 combinations in non-Hodgkin lymphoma \u2013<\/em>\n      <\/p>\n<p>NEW HAVEN, Conn., April  28, 2025  (GLOBE NEWSWIRE) &#8212; Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company working to develop a new class of drugs based on targeted protein degradation, today presented data from preclinical combination studies of ARV-393, the company\u2019s investigational PROteolysis TArgeting Chimera (PROTAC) B-cell lymphoma 6 protein (BCL6) degrader. BCL6 is a transcriptional repressor protein and a known driver of B-cell lymphomas. Data demonstrated synergistic antitumor activity, including complete regressions, in combination with standard of care (SOC) chemotherapy, SOC biologics, and investigational oral small molecule inhibitors (SMIs) in high grade B-cell lymphoma (HGBCL) and aggressive diffuse large B-cell lymphoma (DLBCL) models. The results from these preclinical studies were shared in a poster presentation at the 2025 American Association for Cancer Research (AACR) annual meeting in Chicago, Illinois.<\/p>\n<p>Key findings from the studies included:<\/p>\n<ul type=\"disc\">\n<li>ARV-393 in combination with SOC chemotherapy (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone [R-CHOP]), induced significantly greater tumor growth inhibition compared with rituximab, CHOP, R-CHOP, or ARV-393 alone, with complete tumor regressions in all mice treated with the ARV-393 and R-CHOP combination.<\/li>\n<li>ARV-393 in combination with SOC biologics targeting CD20 (rituximab), CD19 (tafasitamab), or CD79b (polatuzumab vedotin) resulted in tumor regressions and demonstrated significantly stronger tumor growth inhibition compared with each agent alone.<\/li>\n<li>In preclinical models, ARV-393 increased CD20 expression, providing additional support for the exploration of combinations with CD20-targeted agents and in the context of low or loss of CD20 expression.<\/li>\n<li>ARV-393 in combination with investigational small molecule inhibitors targeting clinically validated oncogenic drivers of lymphoma, such as BTK (acalabrutinib), BCL2 (venetoclax), or EZH2 (tazemetostat), resulted in superior tumor growth inhibition compared with each agent alone, with tumor regressions in all mice treated with the combinations.<\/li>\n<\/ul>\n<p>\u201cGiven that combination regimens are the foundation of lymphoma treatment, we are encouraged by the strength of these preclinical combination data, which demonstrate complete tumor regressions in aggressive lymphoma models,\u201d said Noah Berkowitz, M.D., Ph.D., Chief Medical Officer at Arvinas. \u201cWe believe these preclinical data demonstrate potential for broad combinability of ARV-393 and provide a compelling rationale for considering combination strategies as we work to bring forward new therapeutic options for lymphoma patients.\u201d<\/p>\n<p>A Phase 1 study of ARV-393 is enrolling patients with relapsed\/refractory non-Hodgkin lymphoma, including DLBCL (<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=Uyu68uDFkUABeVYsouZcu_0UrNrX4zvpmBVWZkIMsBD7q2rb-2civRbBO-axYFjdxbsLcFncEwiOIScQMlmc5jkFC6N6Zayd2tZUcqtZg7JTAqETQHEz8H-aXGg4sqgxZLtcdndE6nE1o9KGMnAD1yyW3SQLZyGTKDff1JxyruI=\" rel=\"nofollow\" target=\"_blank\">NCT06393738<\/a>).<\/p>\n<p>\n        <strong>Additional detail on the ARV-393 data presentation at AACR 2025:<\/strong>\n      <\/p>\n<p>\n        <strong>Poster Title: <\/strong>ARV-393, a PROteolysis TArgeting Chimera (PROTAC) BCL6 Degrader, Combined With Biologics or Small-Molecule Inhibitors Induces Tumor Regressions in Diffuse Large B-Cell Lymphoma Models<br \/><strong>Abstract: <\/strong>1655<br \/><strong>Session Title:<\/strong> Degraders and Glues 2 <br \/><strong>Session Type:<\/strong> Experimental and Molecular Therapeutic<br \/><strong>Location:<\/strong> Poster Section 18<br \/><strong>Poster Board Number:<\/strong> 15<br \/><strong>Date:<\/strong> Monday, April 28, 2025<br \/><strong>Lecture Time:<\/strong> 9:00 a.m. \u2013 12:00 p.m. CT<\/p>\n<p>\n        <strong>About ARV-393<\/strong><br \/>\n        <br \/>ARV-393 is an investigational, orally bioavailable PROteolysis TArgeting Chimera (PROTAC) designed to degrade B-cell lymphoma 6 protein (BCL6), a transcriptional repressor and major driver of B-cell lymphomas. During B-cell development, tightly controlled BCL6 protein expression regulates &gt;600 genes to facilitate rapid B-cell proliferation and tolerance of somatic hypermutation and gene recombination for antibody generation. Deregulated BCL6 expression is common in B-cell lymphoma and promotes cancer cell survival, proliferation, and genomic instability. PROTAC-mediated degradation has the potential to address the historically undruggable nature of BCL6. ARV-393 is currently in a Phase 1 clinical trial in patients with relapsed\/refractory non-Hodgkin lymphoma.<\/p>\n<p>\n        <strong>About Arvinas<\/strong><br \/>\n        <br \/>Arvinas (Nasdaq: ARVN) is a clinical-stage biotechnology company dedicated to improving the lives of patients suffering from debilitating and life-threatening diseases. Through its PROteolysis TArgeting Chimera (PROTAC) protein degrader platform, the Company is pioneering the development of protein degradation therapies designed to harness the body\u2019s natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. Arvinas is currently progressing multiple investigational drugs through clinical development programs, including vepdegestrant, targeting the estrogen receptor for patients with locally advanced or metastatic ER+\/HER2- breast cancer; ARV-393, targeting BCL6 for relapsed\/refractory non-Hodgkin Lymphoma; and ARV-102, targeting LRRK2 for neurodegenerative disorders. Arvinas is headquartered in New Haven, Connecticut. For more information about Arvinas, visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=cd6jKtY-tLkedqL-JydhI41j575QcAkGGG9ia-NtlZWbxqn_IC38qnPqZIzNzcmPnN_52pC9bxXZG6gzYnYISsXM3UY0iSSrVKiH7i6Cznw=\" rel=\"nofollow\" target=\"_blank\">www.arvinas.com<\/a> and connect on <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=7j1l_Q1EShd5Kf5SEllsuEn9q829Ua6vR9d2NcgOhm-JkCHGgRRpS2UiEOdQwNBy4GoDKMPVAJyGt5pxkYGHiniruaizIhDkqPVS9k8OXsTdvMREtkVXZ9HUmqEaOQ5J\" rel=\"nofollow\" target=\"_blank\">LinkedIn<\/a> and <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=6FxGrkKmuNSbb496tvuzoo3OWPe1rY7IyooDub8Ak94Bizk2P6szIbOcwJaysavZvQxwc9gDteJ_yC5c86-Fng==\" rel=\"nofollow\" target=\"_blank\">X<\/a>.<\/p>\n<p>\n        <strong>Forward-Looking Statements<\/strong><br \/>\n        <br \/>This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995 that involve substantial risks and uncertainties, including statements regarding the potential for Arvinas\u2019 investigational oral PROteolysis TArgeting Chimera (PROTAC) degrader ARV-393 to treat relapsed\/refractory non-Hodgkin lymphoma; the preclinical data for ARV-393 demonstrating the potential for broad combinability and supporting continued evaluation of ARV-393 combinations in non-Hodgkin lymphoma associated with B-cell lymphoma 6 protein (\u201cBCL6\u201d) dysfunction; and PROTAC-mediated degradation having the potential to address the historically undruggable nature of BCL6.. All statements, other than statements of historical facts, contained in this press release, including statements regarding Arvinas\u2019 strategy, future operations, future financial position, future revenues, projected costs, prospects, plans and objectives of management, are forward-looking statements. The words \u201canticipate,\u201d \u201cbelieve,\u201d \u201cestimate,\u201d \u201cexpect,\u201d \u201cintend,\u201d \u201cmay,\u201d \u201cmight,\u201d \u201cplan,\u201d \u201cpredict,\u201d \u201cproject,\u201d \u201ctarget,\u201d \u201cpotential,\u201d \u201cwill,\u201d \u201cwould,\u201d \u201ccould,\u201d \u201cshould,\u201d \u201ccontinue,\u201d and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words.<\/p>\n<p>Arvinas may not actually achieve the plans, intentions or expectations disclosed in these forward-looking statements, and you should not place undue reliance on such forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements Arvinas makes as a result of various risks and uncertainties, including but not limited to: whether Arvinas will be able to successfully conduct and complete development for its product candidates, including ARV-393, including whether Arvinas initiates and completes clinical trials for its product candidates and receives results from its clinical trials on its expected timelines or at all; Arvinas\u2019 ability to protect its intellectual property portfolio; whether Arvinas\u2019 cash and cash equivalent resources will be sufficient to fund its foreseeable and unforeseeable operating expenses and capital expenditure requirements; and other important factors discussed in the \u201cRisk Factors\u201d section of Arvinas\u2019 Annual Report on Form 10-K for the year ended December 31, 2024 and subsequent other reports on file with the U.S. Securities and Exchange Commission. The forward-looking statements contained in this press release reflect Arvinas\u2019 current views with respect to future events, and Arvinas assumes no obligation to update any forward-looking statements, except as required by applicable law. These forward-looking statements should not be relied upon as representing Arvinas\u2019 views as of any date subsequent to the date of this release.<\/p>\n<p>\n        <strong>Contacts:<\/strong><br \/>\n        <br \/>\n        <strong>Investors:<\/strong><br \/>\n        <br \/>Jeff Boyle<br \/>+1 (347) 247-5089<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=vOQK-IiiDRhVPzDt6IOWdygv29vTvR7oWTwYDOUxAa3Mib7YeBz0WUbgNJw9leFe7ZBsKASdWBGj4VCgDczudZJZbhavT2lR7YTaaRkthug=\" rel=\"nofollow\" target=\"_blank\">Jeff.Boyle@arvinas.com<\/a><\/p>\n<p>\n        <strong>Media:<\/strong><br \/>\n        <br \/>Kirsten Owens<br \/>+1 (203) 584-0307<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=E03CEpXATOKorUllRFfUowD-m9YOnq-WPZXtiAW3PTjNZFQC6C-lSI2DclKjeQcfJJyc_oQY45dtkcMgeSFuCq0226QqTWPUyw7Yn5i_l4I2pmVgtXsc9wLxJRR_gWx0\" rel=\"nofollow\" target=\"_blank\">Kirsten.Owens@arvinas.com<\/a><\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQzOTIyOCM2OTA2MDMxIzIxMjIwNzY=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/NzdhMDk2NGQtYzczNS00ZGFhLTg5ZGQtYTkwNTVmZTNhMzY3LTExMzM2NDctMjAyNS0wNC0yOC1lbg==\/tiny\/Arvinas-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>\u2013 ARV-393 demonstrated strong synergistic antitumor activity, including complete regressions, in combination with standard-of-care chemotherapy, biologics, and select investigational oral small molecule inhibitors \u2013 \u2013 Findings support continued evaluation of ARV-393 combinations in non-Hodgkin lymphoma \u2013 NEW HAVEN, Conn., April 28, 2025 (GLOBE NEWSWIRE) &#8212; Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company working to develop a new class of drugs based on targeted protein degradation, today presented data from preclinical combination studies of ARV-393, the company\u2019s investigational PROteolysis TArgeting Chimera (PROTAC) B-cell lymphoma 6 protein (BCL6) degrader. BCL6 is a transcriptional repressor protein and a known driver of B-cell lymphomas. Data demonstrated synergistic antitumor activity, including complete regressions, in combination with standard of care (SOC) chemotherapy, SOC biologics, and &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/arvinas-shares-new-preclinical-combination-data-for-the-protac-bcl6-degrader-arv-393-at-the-2025-american-association-for-cancer-research-annual-meeting\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Arvinas Shares New Preclinical Combination Data for the PROTAC BCL6 Degrader, ARV-393, at the 2025 American Association for Cancer Research Annual Meeting&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-842434","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.9 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Arvinas Shares New Preclinical Combination Data for the PROTAC BCL6 Degrader, ARV-393, at the 2025 American Association for Cancer Research Annual Meeting - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/arvinas-shares-new-preclinical-combination-data-for-the-protac-bcl6-degrader-arv-393-at-the-2025-american-association-for-cancer-research-annual-meeting\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Arvinas Shares New Preclinical Combination Data for the PROTAC BCL6 Degrader, ARV-393, at the 2025 American Association for Cancer Research Annual Meeting - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"\u2013 ARV-393 demonstrated strong synergistic antitumor activity, including complete regressions, in combination with standard-of-care chemotherapy, biologics, and select investigational oral small molecule inhibitors \u2013 \u2013 Findings support continued evaluation of ARV-393 combinations in non-Hodgkin lymphoma \u2013 NEW HAVEN, Conn., April 28, 2025 (GLOBE NEWSWIRE) &#8212; Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company working to develop a new class of drugs based on targeted protein degradation, today presented data from preclinical combination studies of ARV-393, the company\u2019s investigational PROteolysis TArgeting Chimera (PROTAC) B-cell lymphoma 6 protein (BCL6) degrader. BCL6 is a transcriptional repressor protein and a known driver of B-cell lymphomas. Data demonstrated synergistic antitumor activity, including complete regressions, in combination with standard of care (SOC) chemotherapy, SOC biologics, and &hellip; Continue reading &quot;Arvinas Shares New Preclinical Combination Data for the PROTAC BCL6 Degrader, ARV-393, at the 2025 American Association for Cancer Research Annual Meeting&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/arvinas-shares-new-preclinical-combination-data-for-the-protac-bcl6-degrader-arv-393-at-the-2025-american-association-for-cancer-research-annual-meeting\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-04-28T10:48:50+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQzOTIyOCM2OTA2MDMxIzIxMjIwNzY=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/arvinas-shares-new-preclinical-combination-data-for-the-protac-bcl6-degrader-arv-393-at-the-2025-american-association-for-cancer-research-annual-meeting\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/arvinas-shares-new-preclinical-combination-data-for-the-protac-bcl6-degrader-arv-393-at-the-2025-american-association-for-cancer-research-annual-meeting\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Arvinas Shares New Preclinical Combination Data for the PROTAC BCL6 Degrader, ARV-393, at the 2025 American Association for Cancer Research Annual Meeting\",\"datePublished\":\"2025-04-28T10:48:50+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/arvinas-shares-new-preclinical-combination-data-for-the-protac-bcl6-degrader-arv-393-at-the-2025-american-association-for-cancer-research-annual-meeting\\\/\"},\"wordCount\":1116,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/arvinas-shares-new-preclinical-combination-data-for-the-protac-bcl6-degrader-arv-393-at-the-2025-american-association-for-cancer-research-annual-meeting\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQzOTIyOCM2OTA2MDMxIzIxMjIwNzY=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/arvinas-shares-new-preclinical-combination-data-for-the-protac-bcl6-degrader-arv-393-at-the-2025-american-association-for-cancer-research-annual-meeting\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/arvinas-shares-new-preclinical-combination-data-for-the-protac-bcl6-degrader-arv-393-at-the-2025-american-association-for-cancer-research-annual-meeting\\\/\",\"name\":\"Arvinas Shares New Preclinical Combination Data for the PROTAC BCL6 Degrader, ARV-393, at the 2025 American Association for Cancer Research Annual Meeting - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/arvinas-shares-new-preclinical-combination-data-for-the-protac-bcl6-degrader-arv-393-at-the-2025-american-association-for-cancer-research-annual-meeting\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/arvinas-shares-new-preclinical-combination-data-for-the-protac-bcl6-degrader-arv-393-at-the-2025-american-association-for-cancer-research-annual-meeting\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQzOTIyOCM2OTA2MDMxIzIxMjIwNzY=\",\"datePublished\":\"2025-04-28T10:48:50+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/arvinas-shares-new-preclinical-combination-data-for-the-protac-bcl6-degrader-arv-393-at-the-2025-american-association-for-cancer-research-annual-meeting\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/arvinas-shares-new-preclinical-combination-data-for-the-protac-bcl6-degrader-arv-393-at-the-2025-american-association-for-cancer-research-annual-meeting\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/arvinas-shares-new-preclinical-combination-data-for-the-protac-bcl6-degrader-arv-393-at-the-2025-american-association-for-cancer-research-annual-meeting\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQzOTIyOCM2OTA2MDMxIzIxMjIwNzY=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQzOTIyOCM2OTA2MDMxIzIxMjIwNzY=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/arvinas-shares-new-preclinical-combination-data-for-the-protac-bcl6-degrader-arv-393-at-the-2025-american-association-for-cancer-research-annual-meeting\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Arvinas Shares New Preclinical Combination Data for the PROTAC BCL6 Degrader, ARV-393, at the 2025 American Association for Cancer Research Annual Meeting\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Arvinas Shares New Preclinical Combination Data for the PROTAC BCL6 Degrader, ARV-393, at the 2025 American Association for Cancer Research Annual Meeting - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/arvinas-shares-new-preclinical-combination-data-for-the-protac-bcl6-degrader-arv-393-at-the-2025-american-association-for-cancer-research-annual-meeting\/","og_locale":"en_US","og_type":"article","og_title":"Arvinas Shares New Preclinical Combination Data for the PROTAC BCL6 Degrader, ARV-393, at the 2025 American Association for Cancer Research Annual Meeting - Market Newsdesk","og_description":"\u2013 ARV-393 demonstrated strong synergistic antitumor activity, including complete regressions, in combination with standard-of-care chemotherapy, biologics, and select investigational oral small molecule inhibitors \u2013 \u2013 Findings support continued evaluation of ARV-393 combinations in non-Hodgkin lymphoma \u2013 NEW HAVEN, Conn., April 28, 2025 (GLOBE NEWSWIRE) &#8212; Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company working to develop a new class of drugs based on targeted protein degradation, today presented data from preclinical combination studies of ARV-393, the company\u2019s investigational PROteolysis TArgeting Chimera (PROTAC) B-cell lymphoma 6 protein (BCL6) degrader. BCL6 is a transcriptional repressor protein and a known driver of B-cell lymphomas. Data demonstrated synergistic antitumor activity, including complete regressions, in combination with standard of care (SOC) chemotherapy, SOC biologics, and &hellip; Continue reading \"Arvinas Shares New Preclinical Combination Data for the PROTAC BCL6 Degrader, ARV-393, at the 2025 American Association for Cancer Research Annual Meeting\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/arvinas-shares-new-preclinical-combination-data-for-the-protac-bcl6-degrader-arv-393-at-the-2025-american-association-for-cancer-research-annual-meeting\/","og_site_name":"Market Newsdesk","article_published_time":"2025-04-28T10:48:50+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQzOTIyOCM2OTA2MDMxIzIxMjIwNzY=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/arvinas-shares-new-preclinical-combination-data-for-the-protac-bcl6-degrader-arv-393-at-the-2025-american-association-for-cancer-research-annual-meeting\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/arvinas-shares-new-preclinical-combination-data-for-the-protac-bcl6-degrader-arv-393-at-the-2025-american-association-for-cancer-research-annual-meeting\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Arvinas Shares New Preclinical Combination Data for the PROTAC BCL6 Degrader, ARV-393, at the 2025 American Association for Cancer Research Annual Meeting","datePublished":"2025-04-28T10:48:50+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/arvinas-shares-new-preclinical-combination-data-for-the-protac-bcl6-degrader-arv-393-at-the-2025-american-association-for-cancer-research-annual-meeting\/"},"wordCount":1116,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/arvinas-shares-new-preclinical-combination-data-for-the-protac-bcl6-degrader-arv-393-at-the-2025-american-association-for-cancer-research-annual-meeting\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQzOTIyOCM2OTA2MDMxIzIxMjIwNzY=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/arvinas-shares-new-preclinical-combination-data-for-the-protac-bcl6-degrader-arv-393-at-the-2025-american-association-for-cancer-research-annual-meeting\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/arvinas-shares-new-preclinical-combination-data-for-the-protac-bcl6-degrader-arv-393-at-the-2025-american-association-for-cancer-research-annual-meeting\/","name":"Arvinas Shares New Preclinical Combination Data for the PROTAC BCL6 Degrader, ARV-393, at the 2025 American Association for Cancer Research Annual Meeting - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/arvinas-shares-new-preclinical-combination-data-for-the-protac-bcl6-degrader-arv-393-at-the-2025-american-association-for-cancer-research-annual-meeting\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/arvinas-shares-new-preclinical-combination-data-for-the-protac-bcl6-degrader-arv-393-at-the-2025-american-association-for-cancer-research-annual-meeting\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQzOTIyOCM2OTA2MDMxIzIxMjIwNzY=","datePublished":"2025-04-28T10:48:50+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/arvinas-shares-new-preclinical-combination-data-for-the-protac-bcl6-degrader-arv-393-at-the-2025-american-association-for-cancer-research-annual-meeting\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/arvinas-shares-new-preclinical-combination-data-for-the-protac-bcl6-degrader-arv-393-at-the-2025-american-association-for-cancer-research-annual-meeting\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/arvinas-shares-new-preclinical-combination-data-for-the-protac-bcl6-degrader-arv-393-at-the-2025-american-association-for-cancer-research-annual-meeting\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQzOTIyOCM2OTA2MDMxIzIxMjIwNzY=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQzOTIyOCM2OTA2MDMxIzIxMjIwNzY="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/arvinas-shares-new-preclinical-combination-data-for-the-protac-bcl6-degrader-arv-393-at-the-2025-american-association-for-cancer-research-annual-meeting\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Arvinas Shares New Preclinical Combination Data for the PROTAC BCL6 Degrader, ARV-393, at the 2025 American Association for Cancer Research Annual Meeting"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/842434","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=842434"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/842434\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=842434"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=842434"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=842434"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}